Canakinumab for untreated Schnitzler syndrome [ID4063]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Emicizumab for preventing bleeding episodes in people with mild or moderate haemophilia A [ID5098]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
ABP 959 (eculizumab biosimilar) for treating paroxysmal nocturnal haemoglobinuria [TSID10250]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Crizanlizumab for preventing recurrent vaso-occlusive crises in sickle cell disease in young people aged 12 to 17 [TSID10766]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Subcutaneous ravulizumab for treating paroxysmal nocturnal haemoglobinuria or atypical haemolytic uraemic syndrome [TSID11820]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Subcutaneous C1-esterase inhibitor for preventing recurrent attacks of hereditary angioedema in people 12 years and over [TSID11891]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Vonicog alfa for preventing haemorrhage in people with von Willebrand disease when desmopressin is ineffective or not suitable [ID6272]Status:Topic selectionProgramme:Health technology evaluationExpected publication date: TBC
Helge for detecting haemolysisStatus:Topic selectionProgramme:Diagnostics guidanceExpected publication date: TBC
Spectra Optia for plasma exchange, (MT828)Status:Topic selectionProgramme:Medical technologies guidanceExpected publication date: TBC
Ferric maltol for treating iron deficiency anaemia in children and adolescents aged 1 month to 17 years TS ID 11994Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Avatrombopag for treating primary chronic immune thrombocytopenia in people 1 to 17 years [TSID12109]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Berotralstat for preventing recurrent attacks of hereditary angioedema in children aged 2 to 12 years [TSID 12132]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Veverimer for treating metabolic acidosis in chronic kidney disease [ID3832]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC